Biodraft_

Home
Archive
About
Welcome to Biodraft!
A short readme about our biotech blog
 • 
Liang Chang
 and 
Kirill Karlin
New
The “Blockbuster Dilemma” in Biotech
We studied ~10 commercial-stage companies and learned about this interesting theme. Amgen, Genentech, Biogen, Regeneron, Vertex, Gilead, Celgene…
 • 
Liang Chang
 and 
Kirill Karlin
Deep-dive into platform biotech companies: phenotypes, business models, destinations...
We studied over 30 platform companies and share what we have learned. Moderna, Alnylam, Intellia, Recursion, Ginkgo, Kite, Genentech...
 • 
Liang Chang
 and 
Kirill Karlin
2
Therapeutics around the central dogma: DNA
A study note on gene therapy and gene editing landscape: MoA and delivery
 • 
Liang Chang
2
Biodraft_
Biodraft_
Biodraft_ is a biotech blog started by Liang Chang (PhD student at Broad/Harvard) and Kirill Karlin, MD (pathology resident at BIDMC/HMS). As trainees in science/medicine and students in biotechs, we post our monthly biotech analysis on various topics.

Biodraft_

AboutArchiveSitemap
© 2023 Liang Chang and Kirill Karlin
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing